- Home
- SENEA vs ORIC Comparison
SENEA vs ORIC Comparison
Compare SENEA & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SENEA | ORIC |
|---|---|---|
| Founded | 1949 | 2014 |
| Country | United States | United States |
| Employees | 6895 | 104 |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 908.7M | 861.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | SENEA | ORIC |
|---|---|---|
| Price | $140.11 | $8.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $19.73 |
| AVG Volume (30 Days) | 77.2K | ★ 1.2M |
| Earning Date | 06-11-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 19.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.21 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $87.99 | $5.51 |
| 52 Week High | $167.52 | $14.93 |
Technical Indicators
Market Signals| Indicator | SENEA | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 48.04 | 37.06 |
| Support Level | $138.19 | $7.90 |
| Resistance Level | $148.36 | $11.22 |
| Average True Range (ATR) | 5.66 | 0.44 |
| MACD | 0.39 | -0.01 |
| Stochastic Oscillator | 43.78 | 30.75 |
Price Performance
Historical ComparisonAbout SENEA Seneca Foods Corp.
Seneca Foods Corp is a US-based company which acts as a provider of packaged fruits and vegetables. Its product offerings include canned, frozen, and bottled produce and snack chips. The company's segment includes Vegetable and Fruit/Snack. It generates maximum revenue from the Vegetable segment.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.